FAQ

1. Are all EFPIA Japan members now obliged to follow the JPMA transparency guideline?
As an association, EFPIA Japan supports the JPMA Guideline in Japan. This is because transparency in our collaboration with medical societies is important in order to help enhance clarity in governance and eliminate potential misunderstandings and issues related to Conflict of Interest (COI). The JPMA Transparency Guideline is important in ensuring the life-science industry to be transparent because as an industry we are here to serve the lives and well-being of patients and the general public. As for how our support applies to our member firms, we are asking each EFPIA Japan company to respect and make its own decision on how to follow such guidelines and policies.
2. Why is transparency between pharmaceutical companies and medical research communities important?
Transparency in industry-academic collaboration is critical to ensure focus to remain focused on its genuine objective: medical advancements that help patients recover and maintain health. While the industry is driven by adherence to the highest level of ethics, drug development involves painstakingly long processes calling for many stakeholders, many experts, and heavy investment. These processes are therefore vulnerable to being misunderstood not only within the medical research communities and the industry but also by the general public. Transparency highlights the integrity of such research and helps to clarify for the public the critical nature of pharmaceutical companies' collaboration with academia and medical societies.
3. Why is disclosure important for medical and pharmaceutical companies?
As much as patients and the public expect medical and pharmaceutical companies to be open about the processes leading to their health and quality of life-related options, EFPIA Japan strongly believes those working in the medical and pharmaceutical companies want to make sure such expectations are met. Transparency in collaborative work between healthcare companies and medical professionals/institutions is increasingly recognized as a priority globally, at a time when such collaborations become more important than ever to bring medical advancement to patients.
4. Why are donations from pharmaceutical companies necessary? What is a scholarship donation and how different is it from a general donation?
Pharmaceutical companies’ financial support is critical in research conducted by medical communities for medical advancement because development of a single drug require investment of typically 10 to 15 years and funds in the scale of several billion yen to several hundred billions yen.
For more on scholarship donation and general donation, click here
5. Why are donations to academic society necessary?
The process of developing drugs and researching efficacies involve painstaking processes that require investment in many forms -- time, people, and funds. Pharmaceutical companies typically allocate a share of their earnings to supplement the pool of funds available for academic societies to initiate research that help make major medical advancements.
Academic societies also use funds from pharmaceutical companies to augment opportunities for CME -- continuing medical education. Medical experts need to keep continuously updated and educated on key pharmaceutical findings, trends and developments.
6. How complex is drug development? Why does the process large amounts of investment?
Drug development starts from basic research that requires significant time to screen candidate agents. It involves non-clinical trial and 3 phases of clinical trials. This means costs derived from bringing on diverse experts over time spans of at least 3 to 10 years. What is perceived to be high R&D costs is in fact paying for a myriad of expert involvement in diverse ways over many, many years.
EFPIA Japan is proud of advancements in medicine made through academic research, part of which is made possible through the financial support of pharmaceutical companies.
For more on drug development, click here
7. Why do pharmaceutical companies hold lecture and explanation meetings?
Physicians and medical professionals gain updated information on the safe and appropriate use of products from such sessions, which help them treat their patients effectively. Because drug research is continuously evolving, they also need to undergo regular study sessions even after the first launch of a drug.